Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review | Zendy

Shane Mesko | Zendy; Gottfried E. Konecny | Zendy; Paul C. Tumeh | Zendy; Mitchell Kamrava | Zendy

Open Access

Enhanced skin toxicity with concurrent ipilimumab and radiation in vaginal/vulvar melanoma: a case report and literature review

Author(s) -

Shane Mesko,

Gottfried E. Konecny,

Paul C. Tumeh,

Mitchell Kamrava

Publication year - 2016

Publication title -

bjr|case reports

Language(s) - English

Resource type - Journals

ISSN - 2055-7159

DOI - 10.1259/bjrcr.20160002

Subject(s) - ipilimumab , medicine , desquamation , radiation therapy , dermatology , melanoma , toxicity , immunotherapy , cytotoxic t cell , oncology , cancer research , cancer , biology , biochemistry , in vitro

Ipilimumab is a monoclonal cytotoxic T-lymphocyte-associated protein 4 antibody that has demonstrated improved survival in cutaneous melanoma. Little is known about the clinical impact of combining anti-cytotoxic T-lymphocyteassociated protein 4 therapy with radiation. Here we report a case of severe cutaneous desquamation in a 70-year-old female with vaginal/vulvar melanoma receiving concurrent ipilimumab and radiation therapy. The toxicity was successfully treated with oral/topical steroids and a break from treatment. This case underscores the importance of future research on optimal strategies for combining radiation with novel anti-tumour agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research